Anti-LRRC15 Antibodies and Uses Thereof
Published in World Intellectual Property Organization (WIPO) & USPTO, 2026
This patent publication discloses isolated monoclonal antibodies and antigen-binding fragments that specifically target human Leucine-Rich Repeat Containing 15 (LRRC15). The disclosed antibodies exhibit binding affinity, selectivity, and cellular internalization upon engaging LRRC15 expressed on tumor cells and cancer-associated fibroblasts (CAFs).
The patent encompasses multiple molecular formats including full-length antibodies, bispecific/multispecific antibodies, and immunoconjugates, along with methods for diagnosing, prognosing, and treating solid tumors characterized by stromal desmoplasia and LRRC15 expression.
Key Patent Information
- WIPO Publication No.: WO/2026/112469 A1
- PCT Application No.: PCT/US2025/056630
- U.S. Patent Application No.: US 2026/0144885 A1
- Priority Date: November 22, 2024
- Publication Date: May 28, 2026
- Assignee: Bristol-Myers Squibb Company
- Inventors: Sayumi Yamazoe, Sonia G. Tanlimco, Lore Florin, Philip M. Vitorino, Qinqin Cheng, Christine H. Tan, Yuntao Zhang, Sunitha Bachawal, Hok Yee Chan, Winse Hong Morishige, Andrew W. Drake, Deanne M. Lathers, Jaimee C. Wong
Recommended citation: Bristol-Myers Squibb Company (Co-inventor: Yuntao Zhang). (2026). "Anti-LRRC15 Antibodies and Uses Thereof." WIPO Patent Publication No. WO/2026/112469 A1 (U.S. Patent Application No. US 2026/0144885 A1).
Download Paper
Leave a Comment